Comparison 1. Budesonide 6 mg vs placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Maintenance of clinical remission	6		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
1.1 3 months	6	540	Risk Ratio (M‐H, Random, 95% CI)	1.25 [1.00, 1.58]
1.2 6 months	5	420	Risk Ratio (M‐H, Random, 95% CI)	1.15 [0.95, 1.39]
1.3 12 months	5	420	Risk Ratio (M‐H, Random, 95% CI)	1.13 [0.94, 1.35]
1.4 Subgroup (Budesonide Induction) ‐ 3 months	4	290	Risk Ratio (M‐H, Random, 95% CI)	1.23 [1.00, 1.52]
1.5 Subgroup (Medical Induction) ‐ 3 months	5	410	Risk Ratio (M‐H, Random, 95% CI)	1.36 [1.11, 1.68]
1.6 Subgroup (Medical Induction) ‐ 12 months	4	290	Risk Ratio (M‐H, Random, 95% CI)	1.29 [1.00, 1.67]
2 Change in CDAI from baseline	5		Mean Difference (IV, Random, 95% CI)	Subtotals only
2.1 Change after 3 months of treatment	5	420	Mean Difference (IV, Random, 95% CI)	‐15.06 [‐36.04, 5.93]
2.2 Change after 6 months of treatment	5	420	Mean Difference (IV, Random, 95% CI)	‐24.30 [‐46.31, ‐2.29]
2.3 Change after 12 months of treatment	5	420	Mean Difference (IV, Random, 95% CI)	‐23.49 [‐46.65, ‐0.32]
2.4 Subgroup (Medical Induction) ‐ 3 months	4	290	Mean Difference (IV, Random, 95% CI)	‐25.27 [‐43.61, ‐6.94]
2.5 Subgroup (Medical Induction) ‐ 6 months	4	290	Mean Difference (IV, Random, 95% CI)	‐36.56 [‐55.50, ‐17.62]
2.6 Subgroup (Medical Induction) ‐ 12 months	4	290	Mean Difference (IV, Random, 95% CI)	‐34.76 [‐55.42, ‐14.10]
3 Mean Time to Relapse (Days)	4	171	Mean Difference (IV, Random, 95% CI)	59.93 [19.02, 100.84]
4 Withdrawals due to Treatment Failure	6	538	Risk Ratio (M‐H, Random, 95% CI)	0.75 [0.55, 1.03]
5 Proportion of Patients with Treatment‐Related Adverse Events at 12 Months	5	419	Risk Ratio (M‐H, Random, 95% CI)	1.51 [0.90, 2.52]
6 Withdrawals due to Adverse Events	5	466	Risk Ratio (M‐H, Random, 95% CI)	1.08 [0.60, 1.95]
7 Abnormal ACTH Stimulation Test	4	295	Risk Ratio (M‐H, Random, 95% CI)	2.72 [1.62, 4.58]